AutoCyte
This article was originally published in The Gray Sheet
Executive Summary
Amends May 1997 premarket approval application for the Prep liquid-based cytology sample preparation system, the company says Dec. 3. AutoCyte's amendment responds to FDA's request for clarification on Prep's ability to differentiate various levels of cervical disease, and the firm conducted a new study on the liquid-based preparation system's ability to present cellular materials that allow for the correct diagnosis of all levels of cervical abnormality, including low-grade, high-grade and cancerous cervical lesions. AutoCyte is also pursuing U.S. regulatory approval of its Screen computerized image analysis system, which analyzes slides prepared by Prep
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.